Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients

Breast Cancer Research and Treatment

Volumn 36, Issue 1, 1995, Pages 41-48

  Molina, Rafael ^a   Zanón, Gabriel ^a   Filella, Xavier ^a   Moreno, Ferran ^a   Jo, Judith ^a   Daniels, Montserrat ^a   Latre, Maria L ^a   Giménez, Nuria ^a   Pahisa, Jaume ^a   Velasco, Martín ^a   Ballesta, Antonio M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

breast cancer; CA 15.3; CEA; early diagnosis of relapse; metastases; tumor markers; tumor associated antigens

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMAN; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 0029069469     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/BF00690183     Document Type: Article

References (35)

1. On the diagnosis and treatment of breast cancer
2. Kinetics of mammary tumor cell growth and implications for therapy
3. The genetic origin of drug resistance in neoplasms: Implication for systemic therapy
4. The relationship between tumor mass and resistance to chemotherapy
5. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study
6. Serial CEA determinations as an aid in postoperative therapy management of patients with early breast cancer
7. Use of serial carcinoembrionic antigen assays in detecting relapses in breast cancer involving high risk of metastasis
8. Screening for metastases in breast cancer: an assessment of biochemical and physical methods
9. Carcinoembryonic antigen in breast carcinoma patients: serial levels and disease progression
10. Biological markers in breast carcinoma. Clinical correlations with carcinoembryonic antigen
11. Use of serum phosphohexose isomerase and CEA determinations in clinical management of breast cancer
12. Usefulness of the determinations of phosphohexose isomerase and carcinoembryonic antigen in early detection of metastases of breast cancer
13. Differential reactivity of a novel monoclonal antibody (DF-3) with human malignant versus benign breast tumor
14. A sandwich-radioimmunoassay for a new antigen (Mam-6) present in the sera of patients with metastasized carcinomas
15. Development and evaluation of radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115 D8/DF-3
16. A new tumor marker CA 15.3 defined by monoclonal antibodies. Initial clinical evaluation
17. Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer
18. Tumor markers in breast cancer
19. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease
20. Carcinoembryonic antigen (CEA) in clinical medicine. Historical perspectives, pitfalls and projections
21. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease status
22. Circulating CA 15.3 antigen levels in non-mammary malignancies
23. Clinical usefulness of the simultaneous evaluation of serum levels of carcinoembryonic antigen (CEA) and estrogen receptor status in patients with breast cancer
24. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons
25. Histologic grading of breast cancer
26. Mathematical models of drug resistance and chemotherapy effects
27. Adjuvant therapy for breast cancer
28. Carcinoembryonic antigen in patients with breast cancer
29. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma
30. Serial carcinoembryonic antigen determinations in the management of patients with breast cancer
31. Die Bedeutung des CEA für die Therapie und Nachsorge des Mammakarzinom
32. Value of determination of CEA and PHI levels in breast tissue: correlation with steroid receptors
33. Kinetics of human mammary carcinoma and their correlation with the cancer and the host characteristics